Last reviewed · How we verify
5-fluorouracil/oxaliplatin
5-fluorouracil/oxaliplatin is a Chemotherapy combination (antimetabolite + platinum agent) Small molecule drug developed by Seoul National University Hospital. It is currently in Phase 3 development for Colorectal cancer (metastatic and adjuvant settings), Gastric cancer, Pancreatic cancer.
5-fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links, together providing synergistic cytotoxic effects against cancer cells.
5-fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links, together providing synergistic cytotoxic effects against cancer cells. Used for Colorectal cancer (metastatic and adjuvant settings), Gastric cancer, Pancreatic cancer.
At a glance
| Generic name | 5-fluorouracil/oxaliplatin |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Chemotherapy combination (antimetabolite + platinum agent) |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
5-fluorouracil (5-FU) is a pyrimidine antimetabolite that blocks thymidylate synthase, preventing dTMP synthesis and disrupting DNA replication. Oxaliplatin is a third-generation platinum compound that forms interstrand and intrastrand DNA cross-links, leading to apoptosis. The combination (often called FOLFOX when combined with leucovorin and fluorouracil) exploits complementary mechanisms to enhance cytotoxicity against rapidly dividing cancer cells.
Approved indications
- Colorectal cancer (metastatic and adjuvant settings)
- Gastric cancer
- Pancreatic cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Mucositis
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-fluorouracil/oxaliplatin CI brief — competitive landscape report
- 5-fluorouracil/oxaliplatin updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about 5-fluorouracil/oxaliplatin
What is 5-fluorouracil/oxaliplatin?
How does 5-fluorouracil/oxaliplatin work?
What is 5-fluorouracil/oxaliplatin used for?
Who makes 5-fluorouracil/oxaliplatin?
What drug class is 5-fluorouracil/oxaliplatin in?
What development phase is 5-fluorouracil/oxaliplatin in?
What are the side effects of 5-fluorouracil/oxaliplatin?
What does 5-fluorouracil/oxaliplatin target?
Related
- Drug class: All Chemotherapy combination (antimetabolite + platinum agent) drugs
- Target: All drugs targeting Thymidylate synthase (5-FU); DNA (oxaliplatin)
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer (metastatic and adjuvant settings)
- Indication: Drugs for Gastric cancer
- Indication: Drugs for Pancreatic cancer
- Compare: 5-fluorouracil/oxaliplatin vs similar drugs
- Pricing: 5-fluorouracil/oxaliplatin cost, discount & access